Gallbladder cancer – no improvement in survival over time in a Swedish population

Gallbladder cancer (GBC) has an extremely poor outcome. The aim of this study was to examine trends in GBC incidence, treatment and overall survival in a complete population of affected persons in a well-defined region in Sweden in 2000-2014. Altogether 546 individuals with GBC were identified at Sw...

Full description

Saved in:
Bibliographic Details
Published inActa oncologica Vol. 57; no. 11; pp. 1482 - 1489
Main Authors Lindnér, Per, Holmberg, Erik, Hafström, Lo
Format Journal Article
LanguageEnglish
Published England 02.11.2018
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Gallbladder cancer (GBC) has an extremely poor outcome. The aim of this study was to examine trends in GBC incidence, treatment and overall survival in a complete population of affected persons in a well-defined region in Sweden in 2000-2014. Altogether 546 individuals with GBC were identified at Sweden's Regional Cancer Centre West. Subjects were grouped into three 5-year periods (Period A: 2000-2004, Period B: 2005-2009 and Period C: 2010-2014) and the survival, diagnosis, staging, grading and treatment for each period were investigated. Patients dead at date of diagnosis (n = 39) and patients with not invasive cancer (n = 25) were not included in the analysis. The incidence was unchanged over the study period. The survival curves for the time periods were not significantly separated. Median survival was 4.7 months in Period A, 4.8 months in Period B and 6.1 months in Period C. Stage migration to more M1 in Periods B and C occurred and survival was improved for these cohorts. More individuals were diagnosed using only diagnostic imaging (p = .02). There were 177 curatively aiming operative procedures carried out on 482 persons (37%). The survival after surgery for the three periods improved over time (p = .02). Individuals who underwent a liver bed resection after a cholecystectomy had better survival than individuals who had cholecystectomy combined with liver resection. More persons were treated with chemotherapy, but no significant impact was found on survival in the total GBC population. Although there were signs of improved diagnosis of GBC, the survival rate did not improve over time. There was a significant stage migration to more M1 in Periods B and C. Therapeutics able to downsize a cancer and increase the effectiveness of surgery with curative intent are warranted.
AbstractList Gallbladder cancer (GBC) has an extremely poor outcome. The aim of this study was to examine trends in GBC incidence, treatment and overall survival in a complete population of affected persons in a well-defined region in Sweden in 2000-2014.BACKGROUNDGallbladder cancer (GBC) has an extremely poor outcome. The aim of this study was to examine trends in GBC incidence, treatment and overall survival in a complete population of affected persons in a well-defined region in Sweden in 2000-2014.Altogether 546 individuals with GBC were identified at Sweden's Regional Cancer Centre West. Subjects were grouped into three 5-year periods (Period A: 2000-2004, Period B: 2005-2009 and Period C: 2010-2014) and the survival, diagnosis, staging, grading and treatment for each period were investigated. Patients dead at date of diagnosis (n = 39) and patients with not invasive cancer (n = 25) were not included in the analysis.MATERIAL AND METHODSAltogether 546 individuals with GBC were identified at Sweden's Regional Cancer Centre West. Subjects were grouped into three 5-year periods (Period A: 2000-2004, Period B: 2005-2009 and Period C: 2010-2014) and the survival, diagnosis, staging, grading and treatment for each period were investigated. Patients dead at date of diagnosis (n = 39) and patients with not invasive cancer (n = 25) were not included in the analysis.The incidence was unchanged over the study period. The survival curves for the time periods were not significantly separated. Median survival was 4.7 months in Period A, 4.8 months in Period B and 6.1 months in Period C. Stage migration to more M1 in Periods B and C occurred and survival was improved for these cohorts. More individuals were diagnosed using only diagnostic imaging (p = .02). There were 177 curatively aiming operative procedures carried out on 482 persons (37%). The survival after surgery for the three periods improved over time (p = .02). Individuals who underwent a liver bed resection after a cholecystectomy had better survival than individuals who had cholecystectomy combined with liver resection. More persons were treated with chemotherapy, but no significant impact was found on survival in the total GBC population.RESULTSThe incidence was unchanged over the study period. The survival curves for the time periods were not significantly separated. Median survival was 4.7 months in Period A, 4.8 months in Period B and 6.1 months in Period C. Stage migration to more M1 in Periods B and C occurred and survival was improved for these cohorts. More individuals were diagnosed using only diagnostic imaging (p = .02). There were 177 curatively aiming operative procedures carried out on 482 persons (37%). The survival after surgery for the three periods improved over time (p = .02). Individuals who underwent a liver bed resection after a cholecystectomy had better survival than individuals who had cholecystectomy combined with liver resection. More persons were treated with chemotherapy, but no significant impact was found on survival in the total GBC population.Although there were signs of improved diagnosis of GBC, the survival rate did not improve over time. There was a significant stage migration to more M1 in Periods B and C. Therapeutics able to downsize a cancer and increase the effectiveness of surgery with curative intent are warranted.CONCLUSIONSAlthough there were signs of improved diagnosis of GBC, the survival rate did not improve over time. There was a significant stage migration to more M1 in Periods B and C. Therapeutics able to downsize a cancer and increase the effectiveness of surgery with curative intent are warranted.
Gallbladder cancer (GBC) has an extremely poor outcome. The aim of this study was to examine trends in GBC incidence, treatment and overall survival in a complete population of affected persons in a well-defined region in Sweden in 2000-2014. Altogether 546 individuals with GBC were identified at Sweden's Regional Cancer Centre West. Subjects were grouped into three 5-year periods (Period A: 2000-2004, Period B: 2005-2009 and Period C: 2010-2014) and the survival, diagnosis, staging, grading and treatment for each period were investigated. Patients dead at date of diagnosis (n = 39) and patients with not invasive cancer (n = 25) were not included in the analysis. The incidence was unchanged over the study period. The survival curves for the time periods were not significantly separated. Median survival was 4.7 months in Period A, 4.8 months in Period B and 6.1 months in Period C. Stage migration to more M1 in Periods B and C occurred and survival was improved for these cohorts. More individuals were diagnosed using only diagnostic imaging (p = .02). There were 177 curatively aiming operative procedures carried out on 482 persons (37%). The survival after surgery for the three periods improved over time (p = .02). Individuals who underwent a liver bed resection after a cholecystectomy had better survival than individuals who had cholecystectomy combined with liver resection. More persons were treated with chemotherapy, but no significant impact was found on survival in the total GBC population. Although there were signs of improved diagnosis of GBC, the survival rate did not improve over time. There was a significant stage migration to more M1 in Periods B and C. Therapeutics able to downsize a cancer and increase the effectiveness of surgery with curative intent are warranted.
Background: Gallbladder cancer (GBC) has an extremely poor outcome. The aim of this study was to examine trends in GBC incidence, treatment and overall survival in a complete population of affected persons in a well-defined region in Sweden in 2000-2014. Material and methods: Altogether 546 individuals with GBC were identified at Sweden's Regional Cancer Centre West. Subjects were grouped into three 5-year periods (Period A: 2000-2004, Period B: 2005-2009 and Period C: 2010-2014) and the survival, diagnosis, staging, grading and treatment for each period were investigated. Patients dead at date of diagnosis (n = 39) and patients with not invasive cancer (n = 25) were not included in the analysis. Results: The incidence was unchanged over the study period. The survival curves for the time periods were not significantly separated. Median survival was 4.7 months in Period A, 4.8 months in Period B and 6.1 months in Period C. Stage migration to more M1 in Periods B and C occurred and survival was improved for these cohorts. More individuals were diagnosed using only diagnostic imaging (p = .02). There were 177 curatively aiming operative procedures carried out on 482 persons (37%). The survival after surgery for the three periods improved over time (p = .02). Individuals who underwent a liver bed resection after a cholecystectomy had better survival than individuals who had cholecystectomy combined with liver resection. More persons were treated with chemotherapy, but no significant impact was found on survival in the total GBC population. Conclusions: Although there were signs of improved diagnosis of GBC, the survival rate did not improve over time. There was a significant stage migration to more M1 in Periods B and C. Therapeutics able to downsize a cancer and increase the effectiveness of surgery with curative intent are warranted.
Author Lindnér, Per
Hafström, Lo
Holmberg, Erik
Author_xml – sequence: 1
  givenname: Per
  surname: Lindnér
  fullname: Lindnér, Per
  organization: Transplant Institute, Institute of Clinical Sciences Sahlgrenska Academy at University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden
– sequence: 2
  givenname: Erik
  orcidid: 0000-0001-5107-4550
  surname: Holmberg
  fullname: Holmberg, Erik
  organization: Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden
– sequence: 3
  givenname: Lo
  surname: Hafström
  fullname: Hafström, Lo
  organization: Transplant Institute, Institute of Clinical Sciences Sahlgrenska Academy at University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden
BackLink https://www.ncbi.nlm.nih.gov/pubmed/29932778$$D View this record in MEDLINE/PubMed
https://gup.ub.gu.se/publication/274609$$DView record from Swedish Publication Index
BookMark eNp9kc1KxDAUhYMoOo4-gpKlm45JmjYprkT8gwEXKrgLaXqrkfTHpJ3Bne_gG_okts6MCxeuLhy-cy73nn20XTc1IHREyYwSSU4Jk5zK9GnGCJUzyoWkjG-hCU0TGjGWPm2jychEI7SH9kN4JYSwWCS7aI9lWcyEkBN0f62dy50uCvDY6NoM4-vjE9cNtlXrmwVUUHfY1jj0fmEX2uFB87izFYyqxvdLKGx4wW3T9k53tqkP0E6pXYDD9Zyix6vLh4ubaH53fXtxPo9MnPEuEiIDRuNcClGUjJrCgOGM5aLItUwNFdRwgCJNWZloKhLDS5EQLgWUstSaxVMUrXLDEto-V623lfbvqtFWPfetGqTnXgVQTPCUZAN_suKHu956CJ2qbDDgnK6h6YNiJJEJkZTTAT1eo31eQfEbvXncAJytAOObEDyUytju5_rOa-sUJWqsSW1qUmNNal3T4E7-uDcL_vd9A0sDlu0
CitedBy_id crossref_primary_10_1080_00365521_2021_1915373
crossref_primary_10_1089_cbr_2021_0016
crossref_primary_10_1016_j_heliyon_2025_e42853
crossref_primary_10_1007_s12032_022_01874_x
crossref_primary_10_1002_ijc_33980
crossref_primary_10_1136_bmjopen_2020_038634
crossref_primary_10_1186_s12885_025_13711_1
crossref_primary_10_1177_14574969241263539
crossref_primary_10_3389_fonc_2022_889334
crossref_primary_10_1007_s12029_020_00397_w
crossref_primary_10_1055_s_0040_1721180
crossref_primary_10_1097_MD_0000000000034163
crossref_primary_10_2147_JIR_S399586
crossref_primary_10_25259_IJMIO_10_2021
Cites_doi 10.1093/oxfordjournals.annonc.a010676
10.1046/j.1440-1746.2001.02520.x
10.1056/NEJMoa0908721
10.1111/hpb.12444
10.1080/00365521.2017.1284895
10.1634/theoncologist.2009-0302
10.1007/s12094-012-0988-7
10.1186/s12885-015-1617-y
10.1007/s11605-010-1335-3
10.1002/jmri.24537
10.1002/cncr.20160
10.1186/1470-7330-14-14
10.1155/2015/967472
ContentType Journal Article
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ADTPV
AOWAS
F1U
DOI 10.1080/0284186X.2018.1478124
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
SwePub
SwePub Articles
SWEPUB Göteborgs universitet
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1651-226X
EndPage 1489
ExternalDocumentID oai_gup_ub_gu_se_274609
29932778
10_1080_0284186X_2018_1478124
Genre Journal Article
GeographicLocations Sweden
GeographicLocations_xml – name: Sweden
GroupedDBID ---
00X
03L
23M
2WC
36B
4.4
5GY
5RE
6J9
AAFWJ
AALUX
AAMIU
AAPUL
AAWTL
AAYXX
ABDBF
ABEIZ
ABJNI
ABLIJ
ABLJU
ABLKL
ABNNA
ABUPF
ABXYU
ACGEJ
ACGFO
ACGFS
ACIEZ
ACUHS
ADBBV
ADCVX
ADRBQ
ADXPE
AECIN
AEGXH
AENEX
AEOZL
AFKVX
AFPKN
AGDLA
AGFJD
AGYJP
AIAGR
AIJEM
AJWEG
AKBVH
ALMA_UNASSIGNED_HOLDINGS
ALQZU
BABNJ
BAWUL
BLEHA
BOHLJ
CCCUG
CITATION
COF
CS3
DKSSO
EAP
EBB
EBC
EBD
EBS
EBX
EJD
EMB
EMK
EMOBN
EPL
ESX
F5P
GROUPED_DOAJ
H13
HZ~
KRBQP
KSSTO
KWAYT
KYCEM
L7B
M4Z
O9-
OK1
P2P
PGMZT
SV3
TBQAZ
TDBHL
TERGH
TFDNU
TFL
TFW
TUS
UEQFS
V1S
WH7
~1N
.55
.GJ
0BK
3O-
53G
5VS
AALIY
AAPXX
ABFIM
ABWCV
ABZEW
ACCJX
ACENM
ACKZS
ADFOM
ADFZZ
AEIIZ
AEXWM
AFFNX
AFLEI
AJVHN
ALYBC
AWYRJ
BRMBE
CAG
CGR
CUY
CVF
CYYVM
CZDIS
DIK
DRXRE
DWTOO
ECM
EIF
GX1
JENTW
LJTGL
M44
NPM
NUSFT
OVD
RPM
TEORI
X7M
ZGI
ZXP
7X8
ADTPV
AOWAS
F1U
ID FETCH-LOGICAL-c394t-779e213b877df21cdcec422b7dba86c171c4eed662f5a175c4f750487ef8faa23
ISSN 0284-186X
1651-226X
IngestDate Thu Aug 21 07:14:41 EDT 2025
Fri Jul 11 11:00:01 EDT 2025
Thu Jan 02 23:01:24 EST 2025
Tue Jul 01 04:59:46 EDT 2025
Thu Apr 24 23:12:03 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 11
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c394t-779e213b877df21cdcec422b7dba86c171c4eed662f5a175c4f750487ef8faa23
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0001-5107-4550
OpenAccessLink https://www.tandfonline.com/doi/pdf/10.1080/0284186X.2018.1478124?needAccess=true
PMID 29932778
PQID 2058508141
PQPubID 23479
PageCount 8
ParticipantIDs swepub_primary_oai_gup_ub_gu_se_274609
proquest_miscellaneous_2058508141
pubmed_primary_29932778
crossref_citationtrail_10_1080_0284186X_2018_1478124
crossref_primary_10_1080_0284186X_2018_1478124
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2018-11-02
PublicationDateYYYYMMDD 2018-11-02
PublicationDate_xml – month: 11
  year: 2018
  text: 2018-11-02
  day: 02
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Acta oncologica
PublicationTitleAlternate Acta Oncol
PublicationYear 2018
References CIT0010
CIT0001
CIT0011
StataCorp. (CIT0013) 2017
Shabo I (CIT0006) 2001; 98
National Quality Registry for Liver (CIT0002) 2016
Hu L (CIT0015) 2013; 16
John Neil P (CIT0012) 2017
CIT0014
Cancer Research UK (CIT0003)
CIT0005
CIT0016
CIT0004
CIT0018
CIT0017
Hennedige TP (CIT0007) 2014; 14
CIT0009
CIT0008
CIT0019
References_xml – ident: CIT0017
  doi: 10.1093/oxfordjournals.annonc.a010676
– volume: 16
  start-page: 631
  year: 2013
  ident: CIT0015
  publication-title: J Breast Cancer
– ident: CIT0016
  doi: 10.1046/j.1440-1746.2001.02520.x
– ident: CIT0018
  doi: 10.1056/NEJMoa0908721
– ident: CIT0009
  doi: 10.1111/hpb.12444
– ident: CIT0010
  doi: 10.1080/00365521.2017.1284895
– ident: CIT0005
  doi: 10.1634/theoncologist.2009-0302
– ident: CIT0014
  doi: 10.1007/s12094-012-0988-7
– volume-title: Bile Duct and Gallbladder Cancer (SweLiv), Årsrapport nationellt kvalitetsregister
  year: 2016
  ident: CIT0002
– ident: CIT0019
  doi: 10.1186/s12885-015-1617-y
– ident: CIT0004
  doi: 10.1007/s11605-010-1335-3
– volume-title: Adjuvant capecitabine for biliary tract cancer: the BILCAP randomized study. Abstract 4006 ASCO
  year: 2017
  ident: CIT0012
– ident: CIT0008
  doi: 10.1002/jmri.24537
– volume: 98
  start-page: 4584
  year: 2001
  ident: CIT0006
  publication-title: La¨kartidningen
– ident: CIT0011
  doi: 10.1002/cncr.20160
– volume-title: Stata: release 15. Statistical software
  year: 2017
  ident: CIT0013
– volume: 14
  start-page: 14
  year: 2014
  ident: CIT0007
  publication-title: Cancer Imaging
  doi: 10.1186/1470-7330-14-14
– ident: CIT0001
  doi: 10.1155/2015/967472
– volume-title: Gallbladder cancer
  ident: CIT0003
SSID ssj0002375
Score 2.3226511
Snippet Gallbladder cancer (GBC) has an extremely poor outcome. The aim of this study was to examine trends in GBC incidence, treatment and overall survival in a...
Background: Gallbladder cancer (GBC) has an extremely poor outcome. The aim of this study was to examine trends in GBC incidence, treatment and overall...
SourceID swepub
proquest
pubmed
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 1482
SubjectTerms Aged
Aged, 80 and over
Cancer and Oncology
Cancer och onkologi
carcinoma
Cholecystectomy - methods
Female
Gallbladder Neoplasms - epidemiology
Gallbladder Neoplasms - mortality
Gallbladder Neoplasms - pathology
Gallbladder Neoplasms - therapy
Humans
Incidence
Lymph Node Excision
Male
management
Middle Aged
Palliative Care
Proportional Hazards Models
Survival Analysis
Sweden - epidemiology
Title Gallbladder cancer – no improvement in survival over time in a Swedish population
URI https://www.ncbi.nlm.nih.gov/pubmed/29932778
https://www.proquest.com/docview/2058508141
https://gup.ub.gu.se/publication/274609
Volume 57
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELagKyEuiDflJSMhLlVWteM4ybEFlhVikRC7Um-R4zjLipJUaQISv54Z20nDUsTjklZO4qqer59nmplvCHmuUsallsh-CkW1mQnySOhgHumC56WRnGHt8Ml7eXwm3q6i1a7bpq0uafND_X1vXcn_WBXGwK5YJfsPlh0mhQF4D_aFI1gYjn9l4zdqvc7XyB0NZm9p23uuqrH0samtELhtALDtgA--otcJ39B2k8dRNfv4DYtyP802QxOvsau60K2a1ZX27Dhk7kAQX7nH641L8B3Se7G8YUgXay4-79it3Lb2kfxSWvi9q8d_NrDEVt05tjSOIGXEAnDZVmMGdRLTPVLYiA9RZXQvUfvMRtgcWSJXmGKXAGnH6G6Mr4f13nyx1oNtM-Sxa_dzSSG7P3WVHMAL5xNysFi-Wh4NOzIP46iv3kJd9X2fiqrQfp6fXZRf4o5LorLWETm9SW74CIIuHBxukSumuk2unfgciTvkwwgV1KGCBrSq6QgV9KKiPSooooIiKnBUUY8KukPFXXJ29Pr05XHgG2cEOkxFCxFTajgL8ySOi5IzXWijBed5XOQqkZrFTAvwjaTkZaTAf9SiRJX_JDZlUirFw3tkUtWVeUAoRDU6VKUpTGkExOapnqeJKJJSGgWhsJoS0a9Vpr2qPDY3WWesF5_1q53hamd-tafkcLht42RV_nTDs94QGRAgPtVSlam7LVwFES84toJNyX1noWHK3qJT8sKZbDiDqurn3SaDofMu25qMx0LO04e_neIRub77QTwmk7bpzBPwR9v8qYfbD9Z0hIg
linkProvider EBSCOhost
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Gallbladder+cancer+-+no+improvement+in+survival+over+time+in+a+Swedish+population&rft.jtitle=Acta+oncologica&rft.au=Lindn%C3%A9r%2C+Per&rft.au=Holmberg%2C+Erik&rft.au=Hafstr%C3%B6m%2C+Lo&rft.date=2018-11-02&rft.eissn=1651-226X&rft.volume=57&rft.issue=11&rft.spage=1482&rft_id=info:doi/10.1080%2F0284186X.2018.1478124&rft_id=info%3Apmid%2F29932778&rft.externalDocID=29932778
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0284-186X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0284-186X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0284-186X&client=summon